Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years.
作者信息
Vaduganathan Muthiah, Samman Tahhan Ayman, Greene Stephen J, Okafor Maureen, Kumar Sonali, Butler Javed
机构信息
Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA.
Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.
出版信息
Eur J Heart Fail. 2018 Jun;20(6):1068-1071. doi: 10.1002/ejhf.1130. Epub 2018 Jan 4.
Abstract
摘要
相似文献
1
Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years.心力衰竭临床试验的全球化：对16年间开展的305项试验的系统评价
Eur J Heart Fail. 2018 Jun;20(6):1068-1071. doi: 10.1002/ejhf.1130. Epub 2018 Jan 4.
2
Geographic differences in heart failure trials.心力衰竭试验的地域差异。
Eur J Heart Fail. 2015 Sep;17(9):893-905. doi: 10.1002/ejhf.326. Epub 2015 Jul 21.
3
Evolving Issues in Heart Failure Management.
Prog Cardiovasc Dis. 2016 Jan-Feb;58(4):365-6. doi: 10.1016/j.pcad.2016.01.004. Epub 2016 Jan 14.
4
Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review.当代急性心力衰竭试验中肺水肿的评估与患病率：一项系统评价
Eur J Heart Fail. 2015 Sep;17(9):906-16. doi: 10.1002/ejhf.321. Epub 2015 Jul 31.
5
Treatment: special conditions: co-existing heart disease: coronary artery disease, myocardial infarction, heart failure.
J Am Soc Hypertens. 2015 Aug;9(8):651-4; quiz 655. doi: 10.1016/j.jash.2015.06.008. Epub 2015 Jun 17.
6
A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials.急性心力衰竭临床试验中短期终点的评价。
J Card Fail. 2018 Nov;24(11):783-792. doi: 10.1016/j.cardfail.2018.08.007. Epub 2018 Sep 11.
7
Heart Failure With Preserved Ejection Fraction-A Systematic Review and Analysis of Perioperative Outcomes.射血分数保留的心力衰竭——围手术期结局的系统评价与分析
J Cardiothorac Vasc Anesth. 2018 Oct;32(5):2423-2434. doi: 10.1053/j.jvca.2017.11.023. Epub 2017 Nov 20.
8
Updates on Device-Based Therapies for Patients with Heart Failure.心力衰竭患者基于设备的治疗进展
Curr Heart Fail Rep. 2018 Apr;15(2):53-60. doi: 10.1007/s11897-018-0384-x.
9
The challenge of heart failure diagnosis and management in primary care in elderly population: Mere illusion or concrete opportunity?老年人群初级保健中心力衰竭诊断与管理的挑战：纯属幻想还是切实机遇？
Int J Cardiol. 2019 Jan 1;274:248-249. doi: 10.1016/j.ijcard.2018.04.016.
10
Home monitoring should be the central element in an effective program of heart failure disease management.家庭监测应成为心力衰竭疾病管理有效方案的核心要素。
Circulation. 2012 Feb 14;125(6):820-7. doi: 10.1161/CIRCULATIONAHA.111.031161.
引用本文的文献
1
The Changing Landscape of Heart Failure Drug Clinical Trials in China, 2013-2023.2013 - 2023年中国心力衰竭药物临床试验的变化态势
Drug Des Devel Ther. 2025 Apr 3;19:2597-2608. doi: 10.2147/DDDT.S511608. eCollection 2025.
2
Advancing Health Equity in the Cardiovascular Device Life Cycle.在心血管器械生命周期中推进健康公平。
Circ Cardiovasc Qual Outcomes. 2025 Mar;18(3):e011310. doi: 10.1161/CIRCOUTCOMES.124.011310. Epub 2025 Feb 3.
3
Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines.支持急性冠状动脉综合征指南的随机临床试验中的代表性。
Eur Heart J Qual Care Clin Outcomes. 2023 Dec 22;9(8):796-805. doi: 10.1093/ehjqcco/qcad007.
4
Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction.钠-葡萄糖协同转运蛋白2抑制剂对射血分数降低的心力衰竭的全球益处。
JACC Asia. 2022 Apr 19;2(2):154-156. doi: 10.1016/j.jacasi.2022.03.002. eCollection 2022 Apr.
5
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.达格列净在不同主要地理区域慢性肾脏病患者中的疗效与安全性。
Kidney Int Rep. 2022 Feb 2;7(4):699-707. doi: 10.1016/j.ekir.2022.01.1060. eCollection 2022 Apr.
6
Data flow within global clinical trials: a scoping review.全球临床试验中的数据流动：范围综述。
BMJ Glob Health. 2022 Apr;7(4). doi: 10.1136/bmjgh-2021-008128.
7
Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory.提高心力衰竭试验中代表性不足的种族和族裔人群的入组率：心力衰竭协作组的行动呼吁。
JAMA Cardiol. 2022 May 1;7(5):540-548. doi: 10.1001/jamacardio.2022.0161.
8
Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.高、中、低收入国家药物试验评估和新批准药物的当地商业供应情况。
JAMA Netw Open. 2021 May 3;4(5):e217075. doi: 10.1001/jamanetworkopen.2021.7075.
9
Characteristics of Heart Failure Trials Associated With Under-Representation of Women as Lead Authors.与女性作为第一作者代表性不足相关的心力衰竭试验特征。
J Am Coll Cardiol. 2020 Oct 27;76(17):1919-1930. doi: 10.1016/j.jacc.2020.08.062.
10
YB1 protects cardiac myocytes against H2O2‑induced injury via suppression of PIAS3 mRNA and phosphorylation of STAT3.YB1 通过抑制 PIAS3 mRNA 和磷酸化 STAT3 来保护心肌细胞免受 H2O2 诱导的损伤。
Mol Med Rep. 2019 Jun;19(6):4579-4588. doi: 10.3892/mmr.2019.10119. Epub 2019 Apr 3.
本文引用的文献
1
Addressing the Heterogeneity of Heart Failure in Future Randomized Trials.在未来的随机试验中应对心力衰竭的异质性
Curr Heart Fail Rep. 2017 Jun;14(3):197-202. doi: 10.1007/s11897-017-0332-1.
2
Detection and Management of Geographic Disparities in the TOPCAT Trial: Lessons Learned and Derivative Recommendations.TOPCAT试验中地理差异的检测与管理：经验教训及衍生建议
JACC Basic Transl Sci. 2016 Apr;1(3):180-189. doi: 10.1016/j.jacbts.2016.03.001.
3
Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.心力衰竭药物研发的变革：穿越监管十字路口
Circ Heart Fail. 2016 Oct;9(10). doi: 10.1161/CIRCHEARTFAILURE.116.003192.
4
Geographic differences in heart failure trials.心力衰竭试验的地域差异。
Eur J Heart Fail. 2015 Sep;17(9):893-905. doi: 10.1002/ejhf.326. Epub 2015 Jul 21.
5
Trends in Heart Failure Clinical Trials From 2001-2012.2001年至2012年心力衰竭临床试验的趋势
J Card Fail. 2016 Mar;22(3):171-9. doi: 10.1016/j.cardfail.2015.06.014. Epub 2015 Jun 21.
6
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators.改善美国心血管临床试验的开展：临床医生、研究人员、赞助商和监管机构的建议。
Am Heart J. 2015 Mar;169(3):305-14. doi: 10.1016/j.ahj.2014.12.001. Epub 2014 Dec 17.
7
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.TOPCAT 试验中醛固酮拮抗剂治疗心脏收缩功能保留心力衰竭患者及结局的地域差异。
Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18.
8
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.设计针对住院心力衰竭的有效药物和器械研发方案：术前注册研究的建议。
Am Heart J. 2014 Aug;168(2):142-9. doi: 10.1016/j.ahj.2014.05.009. Epub 2014 May 24.
9
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.临床试验现场入组与参与者特征、方案完成情况和结局的关系：EVEREST（血管加压素拮抗剂治疗心力衰竭的疗效：托伐普坦结局研究）试验的结果。
J Am Coll Cardiol. 2013 Feb 5;61(5):571-9. doi: 10.1016/j.jacc.2012.10.025. Epub 2012 Dec 12.
Zotero 插件